Depomed Inc

Depomed — Investor Presentation (January 2012)

29 slides from Depomed's investor presentation, Jan 9, 2012

  1. Slide 1: An Emerging Specialty Pharmaceutical Leader

    Confidential Information January 9, 2012 An Emerging Specialty Pharmaceutical Leader

  2. Slide 2: Note on Forward-Looking Statements

    Statements made in this presentation that are not historical facts are forward-looking statements that involve risks and uncertainties. The inclusion of forward-looking statements, including those related to our commercialization plans for GraliseTM, our clinical development programs, potential bene

  3. Slide 3: Depomed Investment Opportunity

    Depomed Investment Opportunity Establishing leadership in the CNS specialty pharmaceutical sector Building a successful, profitable, product-focused pharmaceutical business Delivering sustainable value to stakeholders: patients/families, physicians, providers, payers, shareholders, employees Strong

  4. Slide 4: 3 in 3 Business Model: 3-Pronged Growth Strategy

    3 in 3 Business Model: 3-Pronged Growth Strategy Grow top line Achieve commercial success of branded marketed products Gralise in PHN: cornerstone of CNS-focused franchise, with realizable $100 million+ market potential Grow bottom line “Cash cow” Glumetza strategy: restructured Santarus agreement p

  5. Slide 5: 3-Year Plan to Sustained Profitability and Shareholder ROI: 2011

    3-Year Plan to Sustained Profitability and Shareholder ROI 2011: Setting the Stage Pivotal year assembling the building blocks of CNS franchise business Reacquired, successfully launched flagship product Gralise with pharma-quality commercial implementation Early indicators: market uptake ramping ni

  6. Slide 6: 2012: Execution

    2012: Execution Grow Gralise market penetration – keys to growth Pain specialists Neurologists Managed care Deals build on track record of > $230 million cash received from in non-dilutive deals since 2006 Grow CNS franchise Opportunistically acquire selective, financially sound assets Depomed, Inc.

  7. Slide 7: 2013: Aggressive Growth

    2013: Aggressive Growth Establish Gralise year-end run rate of $100+ million Glumetza contributing potentially $40+ million to bottom line Selective acquisition or development of portfolio assets with immediate or near-term revenue potential Meaningful valuation and EPS growth: reaching cash-positiv

  8. Slide 8: 2014: Leadership

    2014: Leadership Depomed established as a successful, profitable mid-sized specialty pharmaceutical company Expanded portfolio of assets with significant growth potential, driving sales and profitability Continue to deliver significant shareholder value Depomed, Inc. | January 9, 2012 | Page 8

  9. Slide 9: A Potential New Standard of Care in PHN

    A Potential New Standard of Care in PHN Large market opportunity Clinical differentiation; unmet medical need Pharma-quality pre-launch and launch (October 2011) 164 rep sales force targeting all customer segments: physicians, payors, pharmacies Post-launch monitoring and adjustments as needed Depom

  10. Slide 10: Large Market Opportunity

    Large Market Opportunity Gabapentin + Lyrica > $2 billion market ~38 million prescriptions annually in the US US gross sales for target market ($ billions) Depomed, Inc. | January 9, 2012 | Page 10

  11. Slide 11: Clinically Differentiated

    Clinically Differentiated Effective 24-hour pain control Significant and lasting improvement in pain scores in clinical studies Once-daily dosing with an evening meal Patented polymer technology allows for peak plasma levels during the night and low rates of side effects during the day Favorable tol

  12. Slide 12: Effective, 24-Hour PHN Pain Control with Once-Daily Gabapentin

    Effective, 24-Hour PHN Pain Control with Once-Daily Gabapentin Gralise (1800mg) Neurontin (1800-2400mg) Lyrica (15-300mg) Reduction in Pain Score(1) -2.4 -2.2 to -2.3 -1.8 to -2.2 Dosing 1x daily dosing 3 to 4x daily dosing 2 to 3x daily dosing Dizziness 10.9% 31% - 33% 12% - 28% Somnolence 4.5% 17%

  13. Slide 13: Starter Pack Simplifies Titration for Doctors and Patients

    Starter Pack Simplifies Titration for Doctors and Patients The 30-Day Starter “G-Pack” guides patients through the 2-week titration period and 2 weeks of therapy at the recommended dose of 1800 mg. Comes with clear instructions for patients on when to increase the Gralise dose. Depomed, Inc. | Janua

  14. Slide 14: Market Addressable with Sales Reps

    Market Addressable with 164 Sales Reps Decile 3-10 Neurologists, Pain Specialists; Decile 5-10 PCPs; further segmented based on behavioral characteristics and treatment patterns. Written by target prescribers. Addressable Rx Market: Gabapentin and Lyrica ~23 million TRx(2) Neurologists, Pain Special

  15. Slide 15: Positive Physician and Managed Care Reaction

    Physician Reaction to Gralise “I now have a once-a-day preparation of the drug that I’ve been using as a mainstay – sounds great. Biggest problem with gabapentin is it’s three times a day, with the side effects, and suddenly, we’ve got it once a day...” PCP Interview August 2011 KOL Reaction to Gral

  16. Slide 16: Full Complement of Marketing Materials and Support Initiatives for Launch

    Full Complement of Marketing Materials and Support Initiatives for Launch iPad Visual Aid 30-day samples 15-day samples (11/15) File Card Business Card Holder GRALISE Absorption Video Co-Pay Assistance Card Annotated PI Prior Auth. Hotline Depomed, Inc. | January 9, 2012 | Page 16

  17. Slide 17: Well-Stocked and Launched with Broad Managed Care Coverage

    Coverage as of 12/31/2011 8 out of 10 lives have access to Gralise 91% of Commercial Plans have Gralise at Tier 3 or better Managed Care Team Actively Engaged with All Payer Types Government TriCare (9MM lives): $12 co-pay NY Medicaid (5MM beneficiaries) and TX Medicaid (3.2MM beneficiaries): unrest

  18. Slide 18: Solid Growth to Annualized Gross Revenue Run Rate > $5M at Week 10

    Solid Growth to Annualized Gross Revenue Run Rate > $5M at Week 10 Depomed, Inc. | January 9, 2012 | Page 18 $3.4 $3.9 $4.9 $5.2 $- $1.0 M $2.0 M $3.0 M $4.0 M $5.0 M $6.0 M 12/2/2011 12/9/2011 12/16/2011 12/23/2011 Annualized Gross Revenue (prescription basis) Week Ending

  19. Slide 19: TRx Breakdown Shows Strong Specialist Uptake

    TRx Breakdown Shows Strong Specialist Uptake Depomed, Inc. | January 9, 2012 | Page 19 Gralise TRx by Specialty TRx by Payment Type (November 2011)

  20. Slide 20: Taking Share From Others

    Taking Share From Others Depomed, Inc. | January 9, 2012 | Page 20 Gralise Source of Business Patients switching to Gralise were taking: 11% of Gralise patients are refills (continuing therapy) 57% of Gralise patients are switching from an existing therapy (either a gabapentinoid, Lidoderm or Cymbal

  21. Slide 21: More than 1000 Unique Prescribers

    More than 1000 Unique Prescribers at Week 10 Depomed, Inc. | Private & Confidential | 19 Active Prescriber: Prescribing Gralise >0 times in the most recent rolling 4 week period Unique Prescriber: Prescribing Gralise >0 times since launch Source: IMS through 12/16/2011, retail & mail order

  22. Slide 22: Glumetza: Bottom-Line Growth Driver

    Glumetza: Bottom-Line Growth Driver Santarus Glumetza #1 product (>50% of total revenue) eVoucher program (= $10 co-pay) initiated in September 2011 Weekly Glumetza Rx and number of tablets up by 17% Adding 40 sales rep in January (150 reps total) Depomed Cash cow product with significant growth pot

  23. Slide 23: Acuform Technology Platform: Highly Monetizable Asset

    Acuform Gastric Retention Technology is a continuing source of revenue and cash: License Fees Milestones Royalties Five Acuform technology licenses — potential future milestones (2011 – 2015+) and royalties (2012+) Strengthens bottom line with limited expenditure of resources Acuform® Technology Pla

  24. Slide 24: Strong Recurring Revenue from Acuform Technology Deals

    Strong Recurring Revenue from Acuform Technology Deals Janumet XR -- Januvia (sitagliptin) / metformin XR combination NDA approval pending Regulatory filings ex-US in process Modest royalty upon market launch SGLT2 inhibitor / metformin XR combination Additional milestone and royalties Boehringer co

  25. Slide 25: Strong IP/Regulatory Protection for Marketed Products

    Strong IP/Regulatory Protection for Marketed Products Glumetza 500mg - Depomed formulation 4 Orange Book listed technology patents expiring 2016 - 2021 1000mg - Valeant formulation 2 Orange Book listed patents listed expiring 2021 and 2025 Gralise Depomed proprietary formulation 6 Orange Book listed

  26. Slide 26: Serada for Menopausal Hot Flashes

    Serada® for Menopausal Hot Flashes Breeze 3 top line data announced October 2011 Three of four co-primary endpoints met Two key secondary endpoints not met All met on ANCOVA analysis Further evaluation ongoing Analyzing Breeze 3 data Compiling combined data from Breeze 3 and two prior trials Plan to

  27. Slide 27: Strong Balance Sheet

    Cash position: $154.2 million on 9/30/2011 No debt Strong Balance Sheet Depomed, Inc. | January 9, 2012 | Page 27

  28. Slide 28: Depomed Today

    Depomed Today Commercially attractive, new product launch successfully underway Solid base of business with significant growth potential Strong balance sheet Strong and defensible IP position Multiple value-creating milestones upcoming Experienced, proven leadership team aggressively pursuing realis

  29. Slide 29: An Emerging Specialty Pharmaceutical Leader

    Confidential Information January 9, 2012 An Emerging Specialty Pharmaceutical Leader

Depomed — Investor Presentation (January 2012) on 6ix